BriaCell Therapeutics (BCTX) Stock
BriaCell Therapeutics Chart
Company Profile
Price: $3.45
Market Cap: $12.80M
Exchange: NASDAQ
CEO: Dr. William V. Williams M.D.
Sector: Healthcare
Industry: Biotechnology
Employees: 16
Headquarters: West Vancouver, BC
Website: BriaCell Therapeutics
Business Summary
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
BriaCell Therapeutics News
Biotechs on the Brink: 2 Stocks With Huge Potential
Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and other medical products, but the process can be slow and, for those on the outside, opaque. Then, if all goes according to plan, these firms may see success in the form of promising data, successful trial results, or approval from a regulatory agency like the FDA.
BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for BRIACELL THERAP (BCTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2024 held on February 5, 2025 (the “Meeting”). A total of 36.26% of the Company's issued and outstanding common shares (the “Common Shares”) were voted at the Meeting.
BriaCell Therapeutics Announces Closing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. The Company received gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, of $3.05 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
BriaCell Therapeutics Announces Pricing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. Total gross proceeds from the offering, before deducting placement agent fees and other offering expenses, are expected to be $3.05 million. The offering is expected to close on February 5, 2025, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares in a best-efforts public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce an unprecedented clinical response including resolution of a lung metastasis (breast cancer tumor that spread to the lung) with stable disease elsewhere. This patient is the first metastatic breast cancer (MBC) patient treated with Bria-OTS™.
BriaCell Announces Completion of 15:1 Share Consolidation
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announces that on January 24, 2025 (the “Effective Date”), the Company completed a share consolidation (the “Consolidation”) of the Company's issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every fifteen (15) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the suspension of mail service in Canada from the nationwide strike of the Canadian Union of Postal Workers that commenced on November 15, 2024.
BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. (“BriaPro” or the “Company”), a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the “Meeting Materials”) for its upcoming annual general meeting (the “Meeting”) to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:30 a.m. (EST) due to the suspension of mail service in Canada from the nationwide strike of the Canadian Union of Postal Workers that commenced on November 15, 2024. The Meeting Materials have been posted under the Company's profile on SEDAR+ at www.sedarplus.ca (“SEDAR+”) and on the Company's website at https://investors.briacell.com/briapro.
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warrants have an exercise price of $0.9375 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. Total gross proceeds from the offering, before deducting the underwriter's discounts and other offering expenses, is $5.55 million.
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, highlights the infiltration of cancer fighting immune cells into tumors, using leading CD8 ImmunoPET imaging technology, in its poster presentation at the 2024 San Antonio Breast Cancer Symposium ® at Henry B. Gonzalez Convention Center, San Antonio, TX.
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering
PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warrants will have an exercise price of $0.9375 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the common shares and associated warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting underwriters discounts and other offering expenses, are expected to be approximately $5.55 million. The offering is expected to close on December 13, 2024, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
BriaCell Therapeutics Announces Proposed Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares and warrants in an underwritten public offering. All of the common shares and warrants are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to showcase its impressive survival and clinical benefit data in MBC patients, including those with CNS metastases, treated with the Bria-IMT™ plus CPI regimen. The data is featured in BriaCell's “Spotlight” poster presentation session, at the 2024 San Antonio Breast Cancer Symposium® (SABCS®) held at Henry B. Gonzalez Convention Center, San Antonio, TX.
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor safety data of a clinical study to determine if a study should continue, be modified, or be halted early, has completed its first review of safety events in patients enrolled in BriaCell's pivotal randomized Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor (CPI) combination regimen (NCT06072612). The DSMB issued a statement recommending continuation of the study in metastatic breast cancer patients. BriaCell's pivotal Phase 3 study is currently being conducted under Fast Track Designation with the Food and Drug Administration (FDA).
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 26, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be highlighting its positive overall survival and clinical benefit data in metastatic breast cancer (MBC) patients including those with CNS metastasis (not shown on the abstracts) who were treated with the Bria-IMT™ plus immune checkpoint inhibitor (CPI) combination in its “Spotlight” poster presentation session, at the 2024 San Antonio Breast Cancer Symposium® (SABCS®) held at Henry B. Gonzalez Convention Center, San Antonio, TX.
BriaCell Provides Update to its Board of Directors
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted the resignation of Mr. Marc Lustig, MSc, MBA from the Board of Directors, effective immediately. The Board thanks Marc for his strong contributions to the Company over his tenure.
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) a clinical-stage biotech company that develops novel immunotherapies to transform cancer care, announces that the first patient was dosed in its Phase 1/2 study (ClinicalTrials.gov identifier: NCT06471673) to evaluate the safety and efficacy of Bria-OTS™, BriaCell's personalized next generation immunotherapy. The study will investigate Bria-OTS™ alone and in combination with immune check point inhibitor tislelizumab® (manufactured and supplied by BeiGene, Ltd.) for the treatment of metastatic breast cancer. Bria-OTS™ is an enhanced form of Bria-IMT™, currently in pivotal Phase 3 study for metastatic breast cancer.
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-BRES+™ and Bria-PROS+™, respectively, during a poster session at the 2024 Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces five posters, including a Spotlight poster presentation, at the San Antonio Breast Cancer Symposium® (SABCS®) 47th Annual Meeting, being held December 10 – 13 , 2024, at the Henry B. Gonzalez Convention Center, San Antonio, Texas.
BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns
BriaCell Therapeutics' lead candidate, Bria-IMT, shows promising trial results for metastatic breast cancer, potentially doubling overall survival and median progression-free survival. Despite a market cap below $30 million, BriaCell could tap into a $1-$5 billion market upon approval, with valuations between $1-$2 billion. Financing and shareholder dilution remain significant concerns, with recent offerings raising $18.5 million but also massively increasing the share count.
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, outperforming patients, and survival rates in its Phase 2 metastatic breast cancer (MBC) study.
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today provides a clinical engagement update of its pivotal Phase 3 study of Bria-IMT™ in combination with immune check point inhibitor in metastatic breast cancer (MBC). The study will enroll up to 354 patients randomized 1:1 to the BriaCell combination regimen or physician's choice and will include a small number (n=50) of patients randomized to Bria-IMT™ monotherapy.
BriaCell Therapeutics Announces Closing of $5 Million Offering
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering of 5,128,500 common shares and warrants to purchase up to 5,128,500 common shares at a combined offering price of $0.975 per share and associated warrant, priced at-the-market under Nasdaq rules. The warrants have an exercise price of $0.85 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are approximately $5 million.
BriaCell Therapeutics Announces $5 Million Offering
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 5,128,500 common shares and warrants to purchase up to 5,128,500 common shares at a combined offering price of $0.975 per share and associated warrant, priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $0.85 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance.
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report dramatic anti-tumor response including complete resolution of temporal lobe breast cancer metastasis in a patient treated in the Phase 2 study of BriaCell's Bria-IMT™ plus an immune checkpoint inhibitor regimen. The patient demonstrated an initial partial response at 2 months in the brain lesion with no detectable disease following 8 and 11 months of treatment.
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce U.S. FDA (FDA) authorization of an Expanded Access Policy (EAP) for metastatic breast cancer (MBC) patients.
BriaCell Therapeutics Earnings
This section highlights BriaCell Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for BriaCell Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | July 31, 2024 | July 31, 2023 | July 31, 2022 | July 31, 2021 | July 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $82.58K | $15.53K | $15.14K | $15.57K | $13.99K |
| Gross Profit | $-82.58K | $-15.53K | $-15.14K | $-15.57K | $-13.99K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $26.75M | $15.34M | $8.02M | $1.32M | $2.22M |
| General and Administrative Expenses | $6.15M | $7.94M | $7.27M | $-3.67M | $-1.37M |
| Selling and Marketing Expenses | $-178.93K | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.97M | $7.94M | $7.27M | $-3.67M | $-1.37M |
| Other Expenses | $- | $- | $-15.29M | $-1.33M | $-2.24M |
| Operating Expenses | $32.73M | $23.27M | $-3.39K | $-3.69M | $-1.38M |
| Cost and Expenses | $32.81M | $23.27M | $-3.39K | $-3.69M | $-1.38M |
| Interest Income | $- | $891.21K | $136.73K | $3.15K | $39 |
| Interest Expense | $- | $- | $979 | $46.09K | $27.00K |
| Depreciation and Amortization | $82.58K | $15.27K | $15.27K | $15.26K | $15.26K |
| EBITDA | $-4.77M | $-30.67M | $-15.13M | $-8.69M | $-3.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-32.81M | $-23.27M | $-15.29M | $3.69M | $1.38M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $28.02M | $2.97M | $3.74M | $-6.84M | $-85.10K |
| Income Before Tax | $-4.79M | $-20.30M | $-11.55M | $3.69M | $1.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $62.85K | $-152.62K | $30.73K | $6.58M | $-72.25K |
| Net Income | $-4.79M | $-20.30M | $-11.58M | $-2.89M | $1.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.29 | $-1.30 | $-0.75 | $-0.64 | $1.94 |
| EPS Diluted | $-0.29 | $-1.30 | $-0.75 | $-0.64 | $1.94 |
| Weighted Average Shares Outstanding | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K |
| Weighted Average Shares Outstanding Diluted | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K |
| SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
| Breakdown | January 31, 2025 | October 31, 2024 | July 31, 2024 | April 30, 2024 | January 31, 2024 | October 31, 2023 | July 31, 2023 | April 30, 2023 | January 31, 2023 | October 31, 2022 | July 31, 2022 | April 30, 2022 | January 31, 2022 | October 31, 2021 | July 31, 2021 | April 30, 2021 | January 31, 2021 | October 31, 2020 | July 31, 2020 | April 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $22.67K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $3.76K | $3.84K | $3.74K | $3.86K | $3.82K | $3.87K | $3.73K | $- | $3.76K | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $22.67K | $-3.76K | $-3.84K | $-3.74K | $-3.86K | $-3.82K | $-3.87K | $-3.73K | $- | $-3.76K | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $5.68M | $3.67M | $4.41M | $7.54M | $8.31M | $6.86M | $5.17M | $3.86M | $3.05M | $3.26M | $2.87M | $2.54M | $1.73M | $875.64K | $594.44K | $406.20K | $93.43K | $116.84K | $418.07K | $202.99K |
| General and Administrative Expenses | $1.48M | $1.49M | $1.36M | $1.57M | $1.57M | $1.65M | $2.54M | $1.82M | $1.43M | $2.15M | $1.37M | $-2.30M | $-2.20M | $-887.22K | $-1.04M | $-2.39M | $-176.39K | $-230.40K | $-203.24K | $-294.83K |
| Selling and Marketing Expenses | $- | $- | $- | $-27.02K | $5.25K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.48M | $1.49M | $1.36M | $1.54M | $1.58M | $1.65M | $2.54M | $1.82M | $1.43M | $2.15M | $1.37M | $-2.30M | $-2.20M | $-887.22K | $-1.04M | $-2.39M | $-176.39K | $-230.40K | $-203.24K | $-294.83K |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.67M | $-2.55M | $3.82K | $431 | $113 | $113 | $4.69K | $4.69K | $-1.96K | $-23.92K |
| Operating Expenses | $7.17M | $5.15M | $5.77M | $9.09M | $9.88M | $8.50M | $7.71M | $5.68M | $4.49M | $5.40M | $5.91M | $-2.30M | $-2.20M | $-891.04K | $-1.04M | $-2.39M | $-180.06K | $-233.91K | $-207.08K | $-298.20K |
| Cost and Expenses | $- | $5.15M | $5.77M | $9.09M | $9.89M | $8.50M | $7.71M | $5.68M | $4.49M | $5.40M | $5.91M | $-2.30M | $-2.20M | $-891.04K | $-1.04M | $-2.39M | $-180.06K | $-233.91K | $-207.08K | $-298.20K |
| Interest Income | $- | $13.05K | $2 | $15.61K | $82.07K | $190.81K | $208.78K | $253.49K | $240.59K | $188.35K | $82.36K | $35.99K | $12.08K | $6.30K | $61 | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $15.03M | $188.35K | $979 | $- | $35.99K | $979 | $-81.00K | $62.46K | $44.00K | $14.50K | $28.33K | $3.56K |
| Depreciation and Amortization | $- | $26.66K | $72.44K | $3.76K | $3.84K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.81K | $4.12K | $3.81K | $3.52K | $3.84K | $3.04K |
| EBITDA | $- | $-5.13M | $-5.70M | $-9.23M | $-9.83M | $-8.50M | $-7.49M | $-5.67M | $-4.48M | $-5.40M | $-6.70M | $-10.01M | $2.20M | $894.86K | $-1.99M | $3.02M | $-186.33K | $-401.79K | $-600.83K | $-497.98K |
| EBITDA Ratio | 0.00% | 0.00% | -25122.45% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $- | $-5.15M | $-5.77M | $-9.09M | $-9.89M | $-8.50M | $-7.71M | $-5.68M | $3.15M | $-5.40M | $-4.23M | $2.30M | $-3.93M | $-2.28M | $-1.59M | $-4.81M | $-273.49K | $-350.75K | $-625.20K | $-501.40K |
| Operating Income Ratio | 0.00% | 0.00% | -25441.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $- | $-649.34K | $4.75M | $10.90M | $1.92M | $17.75M | $4.52M | $-954.52K | $-11.32M | $3.90M | $-9.05M | $-5.89M | $14.81M | $-25.25M | $2.63M | $7.76M | $-45.79K | $-40.95K | $1.57K | $-3.52K |
| Income Before Tax | $-6.29M | $-5.80M | $-1.02M | $1.67M | $-11.40M | $5.96M | $-2.42M | $-4.90M | $-11.88M | $-1.11M | $-17.46M | $2.30M | $2.20M | $891.04K | $1.04M | $2.39M | $180.06K | $233.91K | $207.07K | $298.20K |
| Income Before Tax Ratio | 0.00% | 0.00% | -4490.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $220.43K | $-23.17K | $-39.54K | $-14.50M | $4.82M | $-528.10K | $0 | $-4.30M | $101.41K | $11.52M | $-6.30K | $-979 | $-1.21M | $1.13M | $-8.43M | $132.36K | $-797 | $70.35K |
| Net Income | $-6.29M | $-5.80M | $-1.20M | $1.72M | $-11.36M | $6.00M | $-2.42M | $-4.37M | $-11.88M | $3.19M | $-17.56M | $-9.22M | $2.20M | $891.04K | $1.04M | $2.39M | $180.06K | $233.91K | $207.07K | $298.20K |
| Net Income Ratio | 0.00% | 0.00% | -5311.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-2.33 | $-0.22 | $-0.07 | $0.11 | $-0.71 | $0.37 | $-0.15 | $-0.28 | $-0.77 | $0.21 | $-1.15 | $-0.60 | $0.71 | $0.06 | $-0.71 | $0.49 | $0.03 | $0.30 | $-1.56 | $0.41 |
| EPS Diluted | $-2.33 | $-0.22 | $-0.07 | $0.11 | $-0.71 | $-0.49 | $-0.15 | $-0.28 | $-0.77 | $0.21 | $-1.15 | $-0.59 | $0.71 | $0.06 | $-0.71 | $0.49 | $0.03 | $0.30 | $-1.56 | $0.41 |
| Weighted Average Shares Outstanding | 2.70M | 26.64M | 18.03M | 15.98M | 15.98M | 15.98M | 15.98M | 15.52M | 15.52M | 15.52M | 15.24M | 15.36M | 15.79M | 15.24M | 15.27M | 7.54M | 771.96K | 771.96K | 729 | 721.96K |
| Weighted Average Shares Outstanding Diluted | 2.70M | 26.64M | 18.03M | 15.98M | 15.98M | 16.67M | 15.98M | 15.52M | 15.52M | 15.52M | 15.24M | 15.52M | 15.79M | 15.37M | 15.27M | 7.54M | 771.96K | 771.96K | 730 | 721.96K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | July 31, 2024 | July 31, 2023 | July 31, 2022 | July 31, 2021 | July 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $862.09K | $21.25M | $41.04M | $57.27M | $19.46K |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $862.09K | $21.25M | $41.04M | $57.27M | $19.46K |
| Net Receivables | $1.37M | $717.74K | $24.10K | $12.57K | $- |
| Inventory | $- | $-18.87K | $-24.10K | $1 | $-305 |
| Other Current Assets | $1.42M | $4.98M | $1.28M | $516.89K | $217.70K |
| Total Current Assets | $3.65M | $26.95M | $42.35M | $57.80M | $239.43K |
| Property Plant Equipment Net | $388.18K | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $199.80K | $215.07K | $230.34K | $245.61K | $238.88K |
| Goodwill and Intangible Assets | $199.80K | $215.07K | $230.34K | $245.61K | $238.88K |
| Long Term Investments | $418.49K | $2 | $2 | $2 | $1 |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.21M | $0 | $0 | $0 | $1 |
| Total Non-Current Assets | $2.22M | $215.07K | $230.34K | $245.61K | $238.88K |
| Other Assets | $- | $0 | $- | $- | $- |
| Total Assets | $5.87M | $27.16M | $42.58M | $58.04M | $478.31K |
| Account Payables | $7.17M | $1.12M | $463.28K | $214.12K | $4.25K |
| Short Term Debt | $- | $- | $- | $- | $228.75K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $-4.25K |
| Other Current Liabilities | $290.38K | $677.72K | $741.80K | $480.75K | $3.73M |
| Total Current Liabilities | $7.46M | $1.80M | $941.09K | $556.79K | $3.63M |
| Long Term Debt | $- | $- | $- | $25.99K | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $142.80K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $-191.78K |
| Other Non-Current Liabilities | $1.10M | $29.14M | $31.31M | $199.46K | $208.86K |
| Total Non-Current Liabilities | $1.10M | $29.14M | $31.31M | $225.44K | $142.80K |
| Other Liabilities | $- | $- | $-0 | $- | $1 |
| Total Liabilities | $8.56M | $30.94M | $32.25M | $782.24K | $3.77M |
| Preferred Stock | $- | $- | $- | $- | $1 |
| Common Stock | $72.17M | $69.59M | $65.59M | $54.78M | $11.23M |
| Retained Earnings | $-85.44M | $-80.65M | $-60.35M | $-15.75M | $-16.64M |
| Accumulated Other Comprehensive Income Loss | $-138.68K | $-138.68K | $-138.68K | $-138.68K | $-127.00K |
| Other Total Stockholders Equity | $11.03M | $7.42M | $5.23M | $38.99M | $-783.36K |
| Total Stockholders Equity | $-2.38M | $-3.78M | $10.33M | $57.26M | $-3.29M |
| Total Equity | $-2.69M | $-3.78M | $10.33M | $57.26M | $-3.29M |
| Total Liabilities and Stockholders Equity | $5.87M | $27.16M | $42.58M | $58.04M | $478.31K |
| Minority Interest | $-302.52K | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.87M | $27.16M | $42.58M | $58.04M | $478.31K |
| Total Investments | $418.49K | $2 | $2 | $2 | $1 |
| Total Debt | $- | $- | $- | $25.99K | $228.75K |
| Net Debt | $-862.09K | $-21.25M | $-41.04M | $-57.24M | $209.29K |
Balance Sheet Charts
| Breakdown | January 31, 2025 | October 31, 2024 | July 31, 2024 | April 30, 2024 | January 31, 2024 | October 31, 2023 | July 31, 2023 | April 30, 2023 | January 31, 2023 | October 31, 2022 | July 31, 2022 | April 30, 2022 | January 31, 2022 | October 31, 2021 | July 31, 2021 | April 30, 2021 | January 31, 2021 | October 31, 2020 | July 31, 2020 | April 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $5.01M | $5.79M | $862.09K | $933.04K | $6.21M | $13.65M | $21.25M | $28.17M | $33.50M | $37.45M | $41.04M | $44.53M | $47.98M | $55.49M | $57.27M | $20.08M | $5.72K | $6.45K | $19.46K | $53.50K |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2 | $0 | $0 | $0 | $-1 | $1 |
| Cash and Short Term Investments | $5.01M | $5.79M | $862.09K | $933.04K | $6.21M | $13.65M | $21.25M | $28.17M | $33.50M | $37.45M | $41.04M | $44.53M | $47.98M | $55.49M | $57.27M | $20.08M | $5.72K | $6.45K | $19.46K | $53.50K |
| Net Receivables | $- | $- | $1.37M | $15.23K | $30.14K | $21.41K | $717.74K | $14.90K | $8.93K | $29.70K | $24.10K | $14.53K | $27.17K | $19.33K | $12.57K | $15.81K | $4.64K | $- | $- | $301 |
| Inventory | $- | $- | $- | $1 | $2 | $-21.41K | $-18.87K | $-14.90K | $-8.93K | $- | $874.16K | $403.94K | $-1.38M | $99.92K | $- | $189.31K | $-663.29K | $-57.12K | $0 | $-115.78K |
| Other Current Assets | $2.15M | $2.43M | $1.42M | $4.58M | $5.47M | $4.74M | $4.98M | $1.32M | $429.40K | $742.12K | $1.28M | $1.68M | $306.87K | $406.79K | $516.89K | $1.22M | $203.73K | $211.45K | $217.70K | $151.67K |
| Total Current Assets | $7.16M | $8.22M | $3.65M | $5.51M | $11.67M | $18.41M | $26.95M | $29.50M | $33.94M | $38.22M | $42.35M | $46.23M | $48.32M | $55.92M | $57.80M | $20.80M | $214.09K | $215.86K | $239.43K | $205.47K |
| Property Plant Equipment Net | $342.50K | $365.34K | $388.18K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $192.16K | $195.98K | $199.80K | $203.61K | $207.43K | $211.25K | $215.07K | $218.89K | $222.70K | $226.52K | $230.34K | $234.16K | $237.97K | $241.79K | $245.61K | $249.58K | $243.37K | $237.03K | $238.88K | $234.32K |
| Goodwill and Intangible Assets | $192.16K | $195.98K | $199.80K | $203.61K | $207.43K | $211.25K | $215.07K | $218.89K | $222.70K | $226.52K | $230.34K | $234.16K | $237.97K | $241.79K | $245.61K | $249.58K | $243.37K | $237.03K | $238.88K | $234.32K |
| Long Term Investments | $- | $421.98K | $418.49K | $468.33K | $279.94K | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $1 | $1 |
| Tax Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.67M | $1.21M | $1.21M | $-576 | $-1.27K | $0 | $0 | $0 | $0 | $-0 | $0 | $0 | $- | $- | $- | $-1 | $0 | $-1 | $1 | $-0 |
| Total Non-Current Assets | $2.20M | $2.20M | $2.22M | $671.37K | $486.10K | $211.25K | $215.07K | $218.89K | $222.71K | $226.52K | $230.34K | $234.16K | $237.98K | $241.79K | $245.61K | $249.58K | $243.37K | $237.04K | $238.88K | $234.32K |
| Other Assets | $- | $- | $- | $1 | $- | $0 | $0 | $- | $0 | $- | $- | $0 | $- | $- | $0 | $1 | $- | $1 | $- | $1 |
| Total Assets | $9.36M | $10.41M | $5.87M | $6.19M | $12.16M | $18.62M | $27.16M | $29.72M | $34.16M | $38.45M | $42.58M | $46.46M | $48.55M | $56.16M | $58.04M | $21.05M | $457.46K | $452.89K | $478.31K | $439.80K |
| Account Payables | $- | $4.23M | $7.17M | $6.42M | $3.71M | $433.92K | $1.12M | $995.25K | $582.45K | $791.75K | $463.28K | $463.28K | $- | $240.05K | $214.12K | $- | $- | $- | $4.25K | $- |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $386.56K | $258.76K | $228.75K | $214.50K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.40M | $- |
| Other Current Liabilities | $5.23M | $754.67K | $290.38K | $2.88M | $1.56M | $1.02M | $677.72K | $387.84K | $87.96K | $182.30K | $477.81K | $-96.99K | $605.15K | $191.31K | $480.75K | $169.87K | $3.55M | $3.42M | $3.73M | $2.98M |
| Total Current Liabilities | $5.23M | $4.99M | $7.46M | $6.74M | $3.90M | $1.05M | $1.80M | $1.38M | $670.41K | $974.05K | $941.09K | $366.29K | $605.15K | $431.37K | $556.79K | $169.87K | $3.94M | $3.68M | $3.63M | $3.20M |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $26.96K | $25.99K | $25.99K | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $155.38K | $149.65K | $144.30K | $142.80K | $191.57K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $6.65M | $- | $- | $-191.78K | $- |
| Other Non-Current Liabilities | $905.84K | $1.71M | $1.10M | $5.66M | $16.52M | $15.06M | $29.14M | $34.23M | $34.77M | $27.14M | $31.31M | $278.40K | $248.49K | $306.22K | $199.46K | $225.44K | $- | $- | $208.86K | $-191.57K |
| Total Non-Current Liabilities | $905.84K | $1.71M | $1.10M | $5.66M | $16.52M | $15.06M | $29.14M | $34.23M | $34.77M | $27.14M | $31.31M | $278.40K | $248.49K | $333.19K | $225.44K | $7.06M | $149.65K | $144.30K | $142.80K | $191.57K |
| Other Liabilities | $- | $- | $- | $1 | $1 | $- | $- | $- | $- | $0 | $-0 | $- | $- | $- | $- | $1 | $- | $1 | $1 | $-191.57K |
| Total Liabilities | $6.14M | $6.70M | $8.56M | $12.40M | $20.42M | $16.10M | $30.94M | $35.61M | $35.44M | $28.12M | $32.25M | $644.69K | $853.64K | $764.55K | $782.24K | $7.23M | $4.09M | $3.82M | $3.77M | $3.20M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.65M | $18.40M | $0 | $2 | $1 | $2.24M | $1 |
| Common Stock | $- | $- | $72.17M | $69.39M | $69.17M | $69.59M | $69.59M | $65.59M | $65.59M | $65.59M | $65.59M | $55.85M | $53.94M | $55.36M | $54.78M | $25.29M | $12.13M | $11.59M | $11.23M | $10.86M |
| Retained Earnings | $-97.54M | $-91.25M | $-85.44M | $-83.99M | $-85.42M | $-74.65M | $-80.65M | $-78.23M | $-73.34M | $-61.46M | $-60.35M | $-27.58M | $-22.76M | $-18.14M | $-15.75M | $-14.01M | $-18.11M | $-17.12M | $-16.64M | $-15.59M |
| Accumulated Other Comprehensive Income Loss | $-138.68K | $-138.68K | $-138.68K | $8.65M | $8.23M | $-138.68K | $-138.68K | $-138.68K | $-138.68K | $-138.68K | $-138.68K | $-138.68K | $-138.68K | $-138.68K | $-138.68K | $-85.50K | $28.97K | $-95.30K | $-127.00K | $-194.90K |
| Other Total Stockholders Equity | $100.90M | $95.10M | $11.03M | $-243.37K | $-193.80K | $7.92M | $7.42M | $6.89M | $6.61M | $6.34M | $70.68M | $17.69M | $16.66M | $18.31M | $9.04M | $8.88M | $2.32M | $2.26M | $-3.02M | $2.17M |
| Total Stockholders Equity | $3.23M | $3.71M | $-2.38M | $-5.95M | $-8.02M | $2.72M | $-3.78M | $-5.89M | $-1.28M | $10.33M | $10.33M | $45.82M | $47.70M | $55.39M | $57.26M | $13.82M | $-3.63M | $-3.37M | $-3.29M | $-2.76M |
| Total Equity | $2.85M | $3.38M | $-2.69M | $-6.22M | $-8.27M | $2.52M | $-3.78M | $-5.89M | $-1.28M | $10.33M | $10.33M | $45.82M | $47.70M | $55.39M | $57.26M | $13.82M | $-3.63M | $-3.37M | $-3.29M | $-2.76M |
| Total Liabilities and Stockholders Equity | $9.36M | $10.41M | $5.87M | $6.19M | $12.16M | $18.62M | $27.16M | $29.72M | $34.16M | $38.45M | $42.58M | $46.46M | $48.55M | $56.16M | $58.04M | $21.05M | $457.46K | $452.89K | $478.31K | $439.80K |
| Minority Interest | $-376.03K | $-329.62K | $-302.52K | $-267.18K | $-242.92K | $-205.11K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $9.36M | $10.41M | $5.87M | $6.19M | $12.16M | $18.62M | $27.16M | $29.72M | $34.16M | $38.45M | $42.58M | $46.46M | $48.55M | $56.16M | $58.04M | $21.05M | $457.46K | $452.89K | $478.31K | $439.80K |
| Total Investments | $- | $421.98K | $418.49K | $468.33K | $279.94K | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $0 | $2 | $2 | $2 | $0 | $2 |
| Total Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $26.96K | $- | $- | $26.96K | $25.99K | $25.99K | $386.56K | $258.76K | $228.75K | $214.50K |
| Net Debt | $-5.01M | $-5.79M | $-862.09K | $-933.04K | $-6.21M | $-13.65M | $-21.25M | $-28.17M | $-33.50M | $-37.45M | $-41.01M | $-44.53M | $-47.98M | $-55.46M | $-57.24M | $-20.05M | $380.84K | $252.31K | $209.29K | $160.99K |
Annual Cash Flow
| Breakdown | July 31, 2024 | July 31, 2023 | July 31, 2022 | July 31, 2021 | July 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-4.93M | $-20.30M | $-26.84M | $-428.33K | $-3.69M |
| Depreciation and Amortization | $83.90K | $15.27K | $15.27K | $15.26K | $13.97K |
| Deferred Income Tax | $- | $-1.05M | $- | $-8.86M | $0 |
| Stock Based Compensation | $1.80M | $2.19M | $3.07M | $1.97M | $1.69K |
| Change in Working Capital | $7.05M | $-3.53M | $-391.29K | $-2.28M | $2.45M |
| Accounts Receivables | $- | $5.32K | $-11.43K | $10.15K | $-18.07K |
| Inventory | $- | $-5.32K | $11.43K | $-10.15K | $- |
| Accounts Payables | $6.05M | $660.46K | $249.16K | $-1.41M | $- |
| Other Working Capital | $1.01M | $-4.19M | $-640.46K | $-876.44K | $2.46M |
| Other Non Cash Items | $-28.14M | $-1.07M | $11.66M | $1.84M | $64.65K |
| Net Cash Provided by Operating Activities | $-24.13M | $-23.74M | $-12.48M | $-7.75M | $-1.16M |
| Investments in Property Plant and Equipment | $-456.80K | $3 | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-225.00K | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-681.80K | $- | $- | $- | $0 |
| Debt Repayment | $- | $- | $- | $-330.40K | $22.47K |
| Common Stock Issued | $4.42M | $4.00M | $- | $51.62M | $1.15M |
| Common Stock Repurchased | $- | $-47.29K | $-13.03M | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $1.59K | $6.43M | $13.70M | $- |
| Net Cash Used Provided by Financing Activities | $4.42M | $3.95M | $-3.74M | $65.00M | $1.08M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-40.25K |
| Net Change in Cash | $-20.39M | $-19.79M | $-16.23M | $57.25M | $-124.34K |
| Cash at End of Period | $862.09K | $21.25M | $41.04M | $57.27M | $19.46K |
| Cash at Beginning of Period | $21.25M | $41.04M | $57.27M | $21.25K | $143.80K |
| Operating Cash Flow | $-24.13M | $-23.74M | $-12.48M | $-7.75M | $-1.16M |
| Capital Expenditure | $-456.80K | $3 | $- | $- | $- |
| Free Cash Flow | $-24.58M | $-23.74M | $-12.48M | $-7.75M | $-1.16M |
Cash Flow Charts
| Breakdown | January 31, 2025 | October 31, 2024 | July 31, 2024 | April 30, 2024 | January 31, 2024 | October 31, 2023 | July 31, 2023 | April 30, 2023 | January 31, 2023 | October 31, 2022 | July 31, 2022 | April 30, 2022 | January 31, 2022 | October 31, 2021 | July 31, 2021 | April 30, 2021 | January 31, 2021 | October 31, 2020 | July 31, 2020 | April 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-6.34M | $-5.83M | $-1.25M | $1.69M | $-11.36M | $5.96M | $-2.42M | $-4.90M | $-11.88M | $-1.11M | $-15.75M | $-4.84M | $-3.87M | $-2.39M | $-2.72M | $3.02M | $-357.15K | $-365.25K | $-623.63K | $-376.91K |
| Depreciation and Amortization | $26.66K | $26.66K | $72.48K | $3.76K | $3.84K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.82K | $3.81K | $4.12K | $3.81K | $3.52K | $3.84K | $3.04K |
| Deferred Income Tax | $- | $- | $-173.19K | $- | $-516.63K | $689.82K | $299.99K | $-299.99K | $- | $- | $- | $- | $-90.06K | $105.79K | $-1.07M | $-7.78M | $-2.49M | $- | $0 | $0 |
| Stock Based Compensation | $285.09K | $266.97K | $377.89K | $392.21K | $500.15K | $533.82K | $533.82K | $281.19K | $266.84K | $1.11M | $-130.12K | $1.59M | $1.10M | $518.13K | $-40.56K | $2.01M | $- | $- | $51 | $146 |
| Change in Working Capital | $2.11M | $-2.11M | $1.29M | $3.66M | $1.86M | $180.33K | $-3.95M | $-181.88K | $29.86K | $566.19K | $969.16K | $-1.60M | $264.89K | $-21.10K | $62.78K | $-2.79M | $146.06K | $302.01K | $324.56K | $433.02K |
| Accounts Receivables | $-736.79K | $736.79K | $-736.22K | $14.66K | $-8.80K | $-2.48K | $-4.03K | $-5.90K | $20.86K | $-5.46K | $-12 | $12.39K | $- | $- | $4 | $- | $- | $- | $-33 | $- |
| Inventory | $- | $- | $2.40M | $- | $-2.58M | $182.81K | $4.03K | $5.90K | $-20.86K | $5.46K | $12 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $2.94M | $-2.94M | $748.38K | $2.71M | $3.28M | $-689.82K | $128.49K | $412.80K | $-209.30K | $328.47K | $29.33K | $- | $- | $29.33K | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $-92.44K | $92.44K | $-1.12M | $3.65M | $1.17M | $689.82K | $-4.07M | $-594.68K | $239.16K | $237.72K | $939.83K | $-1.62M | $- | $-50.44K | $62.78K | $- | $- | $- | $324.59K | $- |
| Other Non Cash Items | $-2.00M | $688.16K | $-4.36M | $-10.33M | $2.07M | $-14.97M | $-5.39M | $-239.44K | $7.63M | $-4.12M | $11.58M | $29.91K | $29.91K | $978 | $756.47K | $-3.26K | $18.38K | $6.15K | $3.68K | $1.10K |
| Net Cash Provided by Operating Activities | $-5.92M | $-6.96M | $-4.04M | $-4.96M | $-7.44M | $-7.61M | $-10.92M | $-5.33M | $-3.95M | $-3.54M | $-3.33M | $-4.82M | $-2.56M | $-1.78M | $-1.94M | $-5.54M | $-212.20K | $-53.57K | $-291.50K | $60.39K |
| Investments in Property Plant and Equipment | $- | $- | $-449.64K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $225.00K | $-225.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $220.85K | $-220.85K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-75.00K | $-75.00K | $-453.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-75.00K | $-75.00K | $-456.80K | $-220.85K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-37.14M | $17.12M | $24.64M | $11.87K | $38.77K | $-37.70K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $208 | $- | $214.62K | $- | $154.25K | $- |
| Common Stock Issued | $-11.67M | $11.67M | $4.35M | $- | $- | $- | $- | $1.58K | $- | $- | $- | $- | $- | $- | $21.87M | $29.75M | $36.53M | $- | $35.02K | $-51.04K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $47.29K | $-0 | $-310 | $-47.29K | $-102.67K | $-16.43K | $-10.06M | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.22M | $293.25K | $- | $- | $- | $- | $-3.95M | $1.59K | $-310 | $- | $-101.94K | $1.38M | $5.10M | $-4.95M | $25.92M | $-3.27M | $- | $27.10K | $1 | $77.11K |
| Net Cash Used Provided by Financing Activities | $5.22M | $11.96M | $4.42M | $- | $- | $- | $4.00M | $1.59K | $-310 | $-47.29K | $-159.78K | $1.37M | $-4.95M | $-4.95M | $38.27M | $26.49M | $207.31K | $24.99K | $189.26K | $26.07K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $857.00K | $-875.78K | $3.34K | $15.43K | $63.42K | $-96.90K |
| Net Change in Cash | $-778.61K | $4.93M | $-70.95K | $-5.27M | $-7.44M | $-7.61M | $-6.92M | $-5.33M | $-3.95M | $-3.59M | $-3.49M | $-3.45M | $-7.51M | $-1.78M | $37.19M | $20.07M | $-727 | $-13.15K | $-34.05K | $-17.40K |
| Cash at End of Period | $5.01M | $5.79M | $862.09K | $933.04K | $6.21M | $13.65M | $21.25M | $28.17M | $33.50M | $37.45M | $41.04M | $44.53M | $47.98M | $55.49M | $57.27M | $20.08M | $5.72K | $6.45K | $19.46K | $53.50K |
| Cash at Beginning of Period | $5.79M | $862.09K | $933.04K | $6.21M | $13.65M | $21.25M | $28.17M | $33.50M | $37.45M | $41.04M | $44.53M | $47.98M | $55.49M | $57.27M | $20.08M | $5.72K | $6.45K | $19.59K | $53.50K | $70.90K |
| Operating Cash Flow | $-5.92M | $-6.96M | $-4.04M | $-4.96M | $-7.44M | $-7.61M | $-10.92M | $-5.33M | $-3.95M | $-3.54M | $-3.33M | $-4.82M | $-2.56M | $-1.78M | $-1.94M | $-5.54M | $-212.20K | $-53.57K | $-291.50K | $60.39K |
| Capital Expenditure | $- | $- | $-449.64K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-5.92M | $-6.96M | $-4.49M | $-4.96M | $-7.44M | $-7.61M | $-10.92M | $-5.33M | $-3.95M | $-3.54M | $-3.33M | $-4.82M | $-2.56M | $-1.78M | $-1.94M | $-5.54M | $-212.20K | $-53.57K | $-291.50K | $60.39K |
BriaCell Therapeutics Stock Forecast
Analyst ratings, price targets, and earnings estimates for BCTX.
BCTX Analyst Ratings
Strong Buy
Based on 1 analysts in the past 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
| Date | Analyst | Firm | Price Target | Price When Posted | Upside |
|---|
BriaCell Therapeutics Dividends
Explore BriaCell Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
|
$- | $ | $ | $ | $ |
X4 Pharmaceuticals, Inc.
XFOR
|
$53.99M | $0.32 | $-0.57 | $-1.47 | $2.92 |
Terns Pharmaceuticals, Inc.
TERN
|
$293.04M | $3.45 | $-1.27 | $-5.13 | $1.81 |
Day One Biopharmaceuticals, Inc.
DAWN
|
$881.79M | $8.70 | $-1.02 | $-12.42 | $2.36 |
PDS Biotechnology Corporation
PDSB
|
$56.18M | $1.26 | $-1.39 | $-3.58 | $5.89 |
Inozyme Pharma, Inc.
INZY
|
$64.22M | $1.00 | $-1.62 | $-1.71 | $3.01 |
eFFECTOR Therapeutics, Inc.
EFTR
|
$2.82K | $0.00 | $-16.37 | $-0.71 | $-4.41 |
Elevation Oncology, Inc.
ELEV
|
$29.52M | $0.50 | $-0.78 | $-0.72 | $0.54 |
Mereo BioPharma Group plc
MREO
|
$77.37M | $2.50 | $-0.04 | $-10.34 | $6.03 |
Hepion Pharmaceuticals, Inc.
HEPA
|
$401.42K | $0.04 | $-12.32 | $-0.26 | $1.77 |
HOOKIPA Pharma Inc.
HOOK
|
$14.11M | $1.17 | $-3.47 | $-0.58 | $0.49 |
Related Metrics
Explore detailed financial metrics and analysis for BCTX.